Literature DB >> 2429915

Functional and molecular characterization of a monoclonal antibody against human interleukin 2.

E Brandt, A Altman, M Grünefeld, A J Ulmer, H D Flad.   

Abstract

Human recombinant interleukin 2 (r-IL2) was used as an immunizing antigen to yield a murine monoclonal antibody (mAb) termed BO-7. Although the antibody binds to r-IL2 more avidly, it also reacted strongly with IL2 from natural sources in an enzyme-linked immunosorbent assay (ELISA), allowing the detection of the purified lymphokine at sensitivity levels closely approaching those found with the IL2 biological assay. Binding to the antigen is specific, as deduced from the close correlation of ELISA immunoreactivity with IL2 biological activity and from immunoblot analysis of electrophoretically separated IL2 from various sources. Binding studies with synthetic IL2-derived peptides revealed the location of the epitope, which is recognized by mAb BO-7: A peptide representing amino acid residues 59-72 (peptide 84) is strongly reactive with the antibody, while an overlapping peptide (residues 48-69) is not. Peptide 84, moreover, can be applied for immunopurification of mAb BO-7 and competes for binding to the antibody with the intact IL2 molecule. In turn, another monoclonal anti-IL2 antibody (35H10), showing the same reactivity pattern with peptides, competes with mAb BO-7 for binding to IL2. The application of mAb BO-7 as a specific reagent for the quantitation of IL2 in a sandwich-type ELISA is demonstrated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2429915     DOI: 10.1016/S0171-2985(86)80051-1

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  4 in total

1.  Characterization of the epitope specificity of murine monoclonal antibodies directed against lipid A.

Authors:  H M Kuhn; L Brade; B J Appelmelk; S Kusumoto; E T Rietschel; H Brade
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

2.  Inhibitory and stimulatory effects of Pseudomonas aeruginosa pyocyanine on human T and B lymphocytes and human monocytes.

Authors:  A J Ulmer; J Pryjma; Z Tarnok; M Ernst; H D Flad
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

Review 3.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

4.  Modulation of natural and interleukin-2-induced tumour-cytolytic activities by the members of a protein family related to beta-thromboglobulin.

Authors:  A Klein-Struckmeier; J Knüver-Hopf; H Mohr
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.